<DOC>
	<DOCNO>NCT01355315</DOCNO>
	<brief_summary>Enhanced external counterpulsation ( EECP ) noninvasive circulatory assist device treatment option refractory angina leave ventricular ( LV ) dysfunction . Recently , potential role heart failure management show . However , although concept EECP introduce almost four decade ago , despite grow evidence support clinical benefit safety therapeutic modality , little firmly establish regard mechanisms responsible benefit EECP include improvement endothelial function , promotion coronary collateralization , enhancement ventricular function , peripheral effect . Therefore , major aim study provide alternative treatment , EECP , unsuitable standard procedure , especially patient whose heart failure cause repeat myocardial infarction , call ischemic cardiomyopathy ( ICMP ) , evaluate clinical outcome endothelial function 35 hour EECP treatment .</brief_summary>
	<brief_title>Enhanced External Counterpulsation</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>The inclusion criterion leave ventricular ejection fraction ( LVEF ) less 40 % mean leave ventricular angiography symptomatic mildtomoderate heart failure ( New York Heart Association [ NYHA ] functional class IIIII ) . The patient include suitable target either percutaneous coronary intervention surgical bypass grafting . IF he/she moderate severe aortic regurgitation ( AR ) , history deep vein thrombosis , significant arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>EECP</keyword>
	<keyword>ischemic cardiomyopathy</keyword>
	<keyword>endothelin-1</keyword>
	<keyword>ischemia coronary artery disease</keyword>
	<keyword>congestive heart failure amenable standard procedure</keyword>
</DOC>